Medpace Holdings

MEDP on Nasdaq. Medpace Holdings sells clinical trial services to drug and medical device companies. Market value $18.3bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Good business, but not cheap right now

See cheaper Health care stocks on the list

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
3.9%fair

For every $100 of what the whole company costs, it produced $3.91 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 80 of 100. Price score: 55 of 100. Our list needs 70 on quality and 60 on price.

$610.54 a share, 64% above its 1-year low

Over the past year the price has ranged from $373.00 to $693.97.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

0.2
0.4
0.4
0.6
0.7
0.7
2021202220232024202512 monthsto Sep '26
Revenue
$1.1bn$1.5bn$1.9bn$2.1bn$2.5bn
Operating margin
17.4%19.1%17.9%21.2%21.1%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.03bn0.03bn0.03bn0.03bn0.03bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)6 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsStrong, 22.3% a year
  • Buying back its own sharesYes, 10% fewer since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $716 million last quarter, up 9% on a year ago.
  • Profit: $137 million, up 24% on a year ago.
  • It keeps 21 cents of each $1 of sales as operating profit, down from 22 cents a year earlier.
  • Spare cash over the past 12 months: $668 million, down from $677 million.
  • 2% fewer shares than a year ago. Each share owns a bit more of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$537m
March 2025$559m
June 2025$603m
September 2025$660m
December 2025$708m
March 2026$707m
June 2026$707m
September 2026$716m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024$117m
March 2025$115m
June 2025$90m
September 2025$111m
December 2025$135m
March 2026$124m
June 2026$121m
September 2026$137m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
10 February 2026
Next quarterly (estimated, 10-Q)
21 January 2027

Who owns it

7 long-term investors we follow own it, up from 6 last quarter. 696 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

  • August J. Troendle
    Insider or founder
    at least 19.1%−0.9 pts
    (filed with 1 related holder)
    Since 24 September 2026
  • Medpace Investors, LLC
    Insider or founder
    16.6%
    Since 26 November 2025
  • at least 5.0%
    (filed with 1 related holder)
    Since 30 September 2026
  • Sold down below 5%
    Since 30 September 2026
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 9 sold $385m.

  • EWALD STEPHEN P
    General Counsel & Corp. Secy.
    Sold
    Date
    29 October 2026
    Shares
    1,245
    Price
    $690.00
    Value
    $859,050
  • BURWIG SUSAN E
    Exec. VP, Operations
    Sold
    Date
    27 October 2026
    Shares
    3,940
    Price
    $677.00
    Value
    $3m
  • BURWIG SUSAN E
    Exec. VP, Operations
    Sold
    Date
    26 October 2026
    Shares
    16,060
    Price
    $677.00
    Value
    $11m
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    30 September 2026
    Shares
    21,966
    Price
    $625.47
    Value
    $14m
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    29 September 2026
    Shares
    26,701
    Price
    $621.02
    Value
    $17m
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    28 September 2026
    Shares
    2,410
    Price
    $620.07
    Value
    $1m
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    25 September 2026
    Shares
    154
    Price
    $620.60
    Value
    $95,572
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    24 September 2026
    Shares
    27,833
    Price
    $621.33
    Value
    $17m
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    23 September 2026
    Shares
    16,083
    Price
    $628.64
    Value
    $10m
  • Troendle August J.
    President & CEO, Director
    Sold
    Date
    22 September 2026
    Shares
    49,018
    Price
    $628.11
    Value
    $31m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Feb 2026, plus the 10-Q filed 22 Oct 2026 and 5 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.